What we're reading, May 6, 2016: Both Democrats and Republicans are pushing back against the recent Medicare Part B proposal; medical overdose risk is high among people ages 45 to 64; and the Cayman Islands are releasing genetically modified mosquitoes to combat disease.
Both Republicans and Democrats seem unhappy with CMS’ recent Medicare Part B proposal. Dozens of Republicans are demanding the proposal be withdrawn and Democrats have raised their own concerns, according to The Wall Street Journal. The Medicare Part B demonstration also faces opposition from the pharmaceutical industry and patient-advocacy groups. However, there are supporters of the proposal. AARP and Kaiser Permanente with other groups told the administration they thought the test could be a success.
The risk of medical overdose is highest for people between the ages of 45 and 64. NPR reported that for people in this age group, it can be easy to overdose on an opioid if their body has built up a tolerance to the drug and they feel they need to take more to get relief. People in this age group are particularly at risk because of another factor: they may live alone or be isolated due to divorce and adult children moving away.
In the Cayman Islands, the government will release millions of genetically modified mosquitoes to fight against the spread of diseases, such as the Zika virus. The modified mosquitoes have been deployed in Brazil to fight Zika, and tests have already been tested in the Cayman Islands and Panama, reported The Washington Post. Oxitec, the company promoting the use of modified mosquitoes as a safe way to combat mosquito-borne illnesses, and officials in the Florida Keys have proposed testing there as well.
Ruxolitinib Cream Shows Long-Term Safety in AD, Potential for PN Treatment
March 8th 2025Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream (Opzelura; Incyte) in atopic dermatitis (AD), while late-breaking research highlighted its potential efficacy in prurigo nodularis (PN).
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Shaping Dermatology's Future by Increasing Access, Data, and Advocacy
March 7th 2025Thy N. Huynh, MD, FAAD, Bruce A. Brod, MHCI, MD, FAAD, and Melissa Piliang, MD, FAAD, discussed expanding access to pediatric dermatology, dermatology data aggregation, and advocacy for Medicare physician payment reform, respectively.
Read More
Eliminating Enhanced PTCs Would Have Cascading Economic Impacts, Report Estimates
March 6th 2025Enhanced premium tax credits (PTCs) have made marketplace health insurance more affordable, and eliminating them could have sweeping impacts on consumers and the health care industry, according to a new report.
Read More